Alertas Bibliograficas – Diabetes

Standards of Care in Diabetes-2024December 2023, Vol.47, S1-S4.doi:https://doi.org/10.2337/dc24-SINT

Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 DiabetesKutz A, Kim D,Wexler D, Liu J, Schneeweiss S, Glynn R and Patorno EDiabetes Care...

The challenges of identifying and studying type 1 diabetes in adultsThomasJ, Jones ADiabetologia: December;2023;66: 2200 – 2212https://doi.org/10.1007/s00125-023-06004-4

The evolving continuum of dysglycaemia: Non-diabetic hyperglycaemia in older adultsGolding J, Hope S, Chakera A and  Puttana ADiabet Med. 2023 Oct;40(10):e15177.https://doi.org/10.1111/dme.15177

Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell FunctionHerold K, Gitelman S, Gottlieb P, Knetch L, Raymond R, and Ramos EDiabetes Care. 2023 Oct 1;46(10):1848-1856https://doi.org/10.2337/dc23-0675

Review : Incretins beyond type 2 diabetesMathieu Ch and Ahmadzai IDiabetologiahttps://doi.org/10.1007/s00125-023-05980-x

Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous InsulinRosenstock J and OthersN Engl J Med 2023; 389:297-308DOI: 10.1056/NEJMoa2303208

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 TrialJastreboff A, Kaplan L, Frias J, Wu Q, Du Y et alN Engl J Med. 2023 Jun 26. www.doi.org/10.1056/NEJMoa2301972

Global Prevalence of PrediabetesRooney M, Fang M, Ogurstsova K, Ozkan B, Echouffo-Tcheugui EDiabetes Care 2023;46(7):1388–1394DOI: https://doi.org/10.2337/dc22-2376

Implementation of fully closed-loop insulin delivery for inpatients with diabetes: Real-world outcomesBoughton C, Hartnell S, Hobday N, Lake A, Davenport K Et alDiabet Med. 2023 Jun;40(6):e15092.https://doi.org/10.1111/dme.15092